{"id":"soc-soluble-guanylate-cyclase-stimulator","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Soluble guanylate cyclase (sGC) is an intracellular enzyme that produces cyclic GMP (cGMP), a key signaling molecule in vascular smooth muscle relaxation. By directly stimulating sGC independent of nitric oxide availability, these drugs increase cGMP production, leading to smooth muscle relaxation, vasodilation, and improved hemodynamics. This mechanism is particularly beneficial in pulmonary hypertension where endothelial dysfunction impairs the nitric oxide-cGMP pathway.","oneSentence":"Soluble guanylate cyclase stimulators directly activate the enzyme soluble guanylate cyclase to increase intracellular cyclic GMP levels, promoting vasodilation and reducing pulmonary vascular resistance.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:35:08.345Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary arterial hypertension"},{"name":"Chronic thromboembolic pulmonary hypertension"}]},"trialDetails":[{"nctId":"NCT04175600","phase":"PHASE3","title":"A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actelion","startDate":"2020-01-16","conditions":"Hypertension, Pulmonary","enrollment":138},{"nctId":"NCT03738150","phase":"PHASE2","title":"A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","startDate":"2019-04-19","conditions":"Pulmonary Arterial Hypertension","enrollment":21},{"nctId":"NCT03496207","phase":"PHASE2","title":"A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","startDate":"2018-06-13","conditions":"Pulmonary Arterial Hypertension","enrollment":106}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SOC: Soluble guanylate cyclase stimulator","genericName":"SOC: Soluble guanylate cyclase stimulator","companyName":"Actelion","companyId":"actelion","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Soluble guanylate cyclase stimulators directly activate the enzyme soluble guanylate cyclase to increase intracellular cyclic GMP levels, promoting vasodilation and reducing pulmonary vascular resistance. Used for Pulmonary arterial hypertension, Chronic thromboembolic pulmonary hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}